Stem Cells

China Cord Blood Pays $20 Million for Stake in Shandong Cord Blood Bank Feb 25, 2010: China Cord Blood Corporation has acquired a 19.92% equity interest in Shandong Cord Blood Bank (SCBB) for $20.5 million, which will be paid in cash. China Cord Blood already projects an investment yield in this year of 5% or about $1 million from the purchase. More importantly, China Cord Blood also has right of first refusal on future equity interests in SCBB. More details...

Stock Symbol: (NYSE: CO)

NeoStem’s Eyre Subsidiary Approved to Use New Manufacturing Facility Feb 1, 2010: NeoStem reported its China subsidiary, Suzhou Erye Pharma, was approved by the SFDA to begin manufacturing two penicillin products at the company’s new facility. The new plant will allow Eyre to increase production of solvent crystallization sterile penicillin by 50% and freeze-dried raw sterile penicillin by 100%. In the past, these two products have generated 20% of Erye's revenues. More details...

Stock Symbol: (NYSE Amex: NBS)

Beike Biotech Given $1.8 Million Grant for Umbilical Cord Stem Cell Trial Jan 11, 2010: Shenzhen Beike Biotechnology Co. has received a $1.8 million grant to conduct a clinical trial of human umbilical cord mesenchymal stem cells (hUC-MSC) as a treatment for Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS) and other degenerative diseases. The grant was awarded by Jiangsu’s Department of Science and Technology. Beike Biotech’s partners in the project are Jiangsu University and Nanjing University’s Drug Tower Hospital. More details...

China Cord Blood Completes Secondary Offering on NYSE Nov 20, 2009: China Cord Blood Corporation listed its ordinary shares on the New York Stock Exchange and, at the same time, completed a secondary offering. The company placed 3.3 million shares at a price of $6.05 for gross proceeds of $20 million. China allows one cord blood collection license for each major area, and China Cord Blood owns the licenses for Beijing and Guangdong. More details...
Stock Symbol: (NYSE: CO)

NeoStem Closes China Biopharma Acquisition Nov 2, 2009: NeoStem, Inc. announced it has closed its acquisition of China Biopharmaceuticals Holdings, Inc. China Biopharma’s sole asset is a 51% stake in Suzhou Erye Pharmaceutical Co., a 50-year old pharmaceutical company that expects to generate $60 million in revenue and net income of $12 million in 2009. The deal has been in the works for most of the past year. NeoStem is a stem cell storage company based in the US, while Suzhou Erye Pharma boasts a portfolio of 100 products on seven cGMP lines that it markets in China. More details...
Stock Symbols: (NYSE Amex: NBS) (OTCBB: CHBP)

BioTime Investigating Stem Cells to Treat Cancer Oct 22, 2009: BioTime, Inc. announced that Dr. David Jin, Chief Medical Officer of BioTime’s newly formed subsidiary, OncoCyte Corporation, will present the keynote address at the Fifth Chinese Congress on Stem Cell Therapy in Beijing. The presentation, which will be delivered Friday, October 23, will discuss OncoCyte’s technology that uses hemangiogenic stem cell technology to target and destroy tumors. More details...
Stock Symbol: (OTCBB: BTIM)

California and China Agree to Collaborate on Stem Cells Oct 19, 2009: The California Institute for Regenerative Medicine (CIRM) and the Chinese Ministry of Science and Technology (MOST) have agreed to collaborate on stem cell research. The agreement will make it easier to form cross-border teams that are working in similar areas. If the teams’ funding requests are approved, the researchers in each country will be supported by their respective agency, CIRM or MOST. The formal announcement, made today, adds details to a story that ChinaBio® Today originally broke late last week. More details...

Breaking News: California’s $3 Billion Stem Cell Fund Signs MOU with China Oct 17, 2009: In a story postdated to Monday, October 19, 2009, The California Institute for Regenerative Medicine (CIRM) revealed it has signed an agreement to collaborate on stem cell research with China’s Ministry of Science and Technology. The announcement was little more than a headline. A more complete description of the agreement will most likely be released on Monday. More details...

NeoStem Moves Forward on China Biopharma Acquisition Oct 8, 2009: NeoStem, Inc. reported the SEC accepted its registration proposal to acquire China Biopharmaceutical Holdings in an all-stock transaction. China Biopharma’s only asset is a 51% interest in Suzhou Erye Pharmaceutical Co., a generic drug manufacturer that in 2008 produced $50 million in revenues and net income of $8 million. More details...
Stock Symbols: (NYSE Amex: NBS) (OTCBB: CHBP)

BioTime Announces China Stem Cell Subsidiary Sep 23, 2009: BioTime, Inc. will establish a China subsidiary, called BioTime Asia, to market the company’s stem cell products in China and throughout Asia. The company will also seek to develop stem cell therapies for a number of diseases, including the use of genetically modified stem cells to treat currently incurable forms of cancer. BioTime has engaged the services of Dr. Lu Daopei, a prominent China hematologist, to manage the clinical trials of its therapeutic stem cell products. More details...
Stock Symbol: (OTCBB: BTIM)